AC
BNTC icon

Armistice Capital’s Benitec Biopharma BNTC Stock Holding History

Armistice Capital’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60,000
Closed -$551K – 242
2024
Q3 		$551K Buy
+60,000
New +$537K 0.01% 190
2022
Q4 		– Sell
-91,473
Closed -$578K – 203
2022
Q3 		$578K Buy
+91,473
New +$1.16M 0.01% 149

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital's BNTC Position: Q4 2024 in Review

Armistice Capital sold out of Benitec Biopharma (BNTC) in Q4 2024, closing a stake of 60,000 shares — an estimated $551K sold.

Armistice Capital first reported a position in BNTC in Q3 2022 and held it in 2 quarters. The position peaked at $578K in Q3 2022. 30 funds tracked by Wall St. Rank hold BNTC as of Q4 2024.

  • Armistice Capital reported no remaining Benitec Biopharma position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 60,000 Benitec Biopharma shares in Q4 2024, an estimated $551K.
  • Armistice Capital first reported a position in Benitec Biopharma in Q3 2022 and held it in 2 quarters.
  • Armistice Capital's Benitec Biopharma position peaked at $578K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.